TransMedics Group (NASDAQ:TMDX) Trading Down 3.8% – Time to Sell?

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) were down 3.8% on Thursday . The stock traded as low as $61.37 and last traded at $61.50. Approximately 93,896 shares traded hands during mid-day trading, a decline of 91% from the average daily volume of 1,048,580 shares. The stock had previously closed at $63.90.

Wall Street Analyst Weigh In

A number of analysts recently commented on TMDX shares. Canaccord Genuity Group dropped their price target on TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a research note on Wednesday, November 20th. TD Cowen lowered their price objective on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. JPMorgan Chase & Co. restated a “neutral” rating and issued a $75.00 price target (down previously from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. Piper Sandler lowered their price objective on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 11th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a report on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $122.70.

TransMedics Group Stock Performance

The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The stock has a market cap of $2.11 billion, a price-to-earnings ratio of 66.97 and a beta of 2.06. The stock’s 50 day moving average is $84.31 and its two-hundred day moving average is $127.28.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The company had revenue of $108.76 million during the quarter, compared to analysts’ expectations of $115.00 million. During the same quarter last year, the business posted ($0.12) earnings per share. The company’s revenue for the quarter was up 63.7% compared to the same quarter last year. Analysts anticipate that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

Insider Activity at TransMedics Group

In related news, CEO Waleed H. Hassanein sold 8,625 shares of the business’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $132.71, for a total value of $1,144,623.75. Following the completion of the sale, the chief executive officer now directly owns 61,643 shares in the company, valued at approximately $8,180,642.53. The trade was a 12.27 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Tamer I. Khayal sold 1,084 shares of the stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $86.40, for a total transaction of $93,657.60. Following the transaction, the insider now directly owns 20,843 shares in the company, valued at approximately $1,800,835.20. This represents a 4.94 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 19,417 shares of company stock worth $2,240,738 over the last 90 days. Company insiders own 7.00% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. State of Alaska Department of Revenue acquired a new position in shares of TransMedics Group in the 3rd quarter valued at about $2,560,000. Charles Schwab Investment Management Inc. increased its position in shares of TransMedics Group by 2.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 271,694 shares of the company’s stock worth $42,656,000 after acquiring an additional 6,634 shares in the last quarter. Zacks Investment Management purchased a new position in shares of TransMedics Group in the 3rd quarter valued at $1,607,000. Vaughan Nelson Investment Management L.P. boosted its position in TransMedics Group by 24.3% during the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 329,010 shares of the company’s stock worth $51,654,000 after purchasing an additional 64,360 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. increased its holdings in TransMedics Group by 665.1% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 74,625 shares of the company’s stock valued at $11,716,000 after purchasing an additional 64,872 shares in the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.